- Home
- SCPH vs ENGN Comparison
SCPH vs ENGN Comparison
Compare SCPH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- ENGN
- Stock Information
- Founded
- SCPH 2013
- ENGN 1999
- Country
- SCPH United States
- ENGN Canada
- Employees
- SCPH N/A
- ENGN N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- SCPH Health Care
- ENGN
- Exchange
- SCPH Nasdaq
- ENGN Nasdaq
- Market Cap
- SCPH 274.7M
- ENGN 293.1M
- IPO Year
- SCPH 2017
- ENGN N/A
- Fundamental
- Price
- SCPH $3.26
- ENGN $5.83
- Analyst Decision
- SCPH Strong Buy
- ENGN Strong Buy
- Analyst Count
- SCPH 2
- ENGN 8
- Target Price
- SCPH $15.00
- ENGN $30.38
- AVG Volume (30 Days)
- SCPH 544.0K
- ENGN 200.8K
- Earning Date
- SCPH 11-13-2024
- ENGN 12-19-2024
- Dividend Yield
- SCPH N/A
- ENGN N/A
- EPS Growth
- SCPH N/A
- ENGN N/A
- EPS
- SCPH N/A
- ENGN N/A
- Revenue
- SCPH $30,278,000.00
- ENGN N/A
- Revenue This Year
- SCPH $174.12
- ENGN N/A
- Revenue Next Year
- SCPH $133.41
- ENGN N/A
- P/E Ratio
- SCPH N/A
- ENGN N/A
- Revenue Growth
- SCPH 303.87
- ENGN N/A
- 52 Week Low
- SCPH $3.08
- ENGN $4.42
- 52 Week High
- SCPH $6.71
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- SCPH 43.13
- ENGN 26.75
- Support Level
- SCPH $3.11
- ENGN $5.68
- Resistance Level
- SCPH $3.67
- ENGN $6.55
- Average True Range (ATR)
- SCPH 0.21
- ENGN 0.69
- MACD
- SCPH 0.01
- ENGN -0.24
- Stochastic Oscillator
- SCPH 31.54
- ENGN 6.99
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.